Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × apalutamide × Head & Neck × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 98 Thoracic 1 Other hematologic neoplasm 1 Head & Neck 1

Conditions

Salivary Gland Neoplasms 1

Interventions

Cisplatin 616 pembrolizumab 321 Radiotherapy 318 Cetuximab 274 Docetaxel 219 Radiotherapy, Intensity-Modulated 209 Fluorouracil 196 Carboplatin 196 Paclitaxel 158 Nivolumab 137 Gemcitabine 123 Magnetic Resonance Spectroscopy 93 Radiation 84 Drug Therapy 77 Capecitabine 75 toripalimab 72 Surgical Procedures, Operative 62 durvalumab 60 Biopsy 52 Cyclophosphamide 48 Erlotinib Hydrochloride 46 Chemoradiotherapy 46 camrelizumab 45 Specimen Handling 45 Radiosurgery 45 130-nm albumin-bound paclitaxel 43 Standard of Care 42 Platinum 41 tislelizumab 40 Bevacizumab 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04325828 2026-04-13

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡